Document:

<PAGE>

                                                                   EXHIBIT 10.13

            RESEARCH MATERIAL TRANSFER AND COLLABORATION AGREEMENT
            ------------------------------------------------------

Lakaro Biopharmaceuticals, Inc., a corporation organized under the laws of the
State of Delaware, USA, with offices at 787 Seventh Avenue, NY, NY 10019 and 216
Jaffa Road, Jerusalem 94383 Israel ("Lakaro"), will provide research material to
Osteotech, Inc., at 51 James Way, Eatontown, NJ 07724 United States of America
("Investigator") on the terms and conditions set forth in this Research Material
Transfer Agreement ("Agreement").

     1.   Lakaro will generate novel peptides to be used as research material by
the Investigator as described under Section 4 ("Research Materials"). The
Investigator shall also supply Lakaro with an indication of the amount of
specific peptides it anticipates requiring for testing to be performed pursuant
to this Agreement. It is anticipated that the area of focus will be bone
healing, but the scope of the collaboration need not be limited to bone healing.

     2.  Investigator agrees that any and all Research Materials will be used
under suitable containment conditions solely for in vitro and in vivo laboratory
studies or animal testing, and will not be used in humans. Investigator
acknowledges that the Research Materials are not intended for human use and,
pursuant to United States Food and Drug Administration regulations, animals
receiving Research Materials and by-products of such animals may not enter the
food chain. Investigator will comply with all federal, state and local laws and
regulations applicable to the Research Materials.

     3.  The Research Materials are being provided to Investigator pursuant to a
limited license, the sole purpose of which shall be for Investigator to test the
peptides to determine their efficacy in the treatment of diseases related to
bone healing or other diseases identified by the parties. Investigator agrees
that the Research Materials will be used solely to conduct research studies to
determine the feasibility of using the Research Materials concept as it relates
to bone healing and, should the parties so agree, other diseases, as set forth
in more detail in Section 20 ("Research Studies"), and will be used only for
research purposes.  Investigator further agrees that it shall not use the
Research Materials to make peptide derivatives or peptidomimetics and that
Research Materials will not be transferred or provided to third parties outside
the Investigator's premises without Lakaro's prior written approval.

     4.  Lakaro shall generate the Research Materials within two (2) months
after receiving the signed Research Material Transfer Agreement. Investigator
shall have up to four (4) months from receipt of the Research Materials to test
them.

     5.  Investigator will provide Lakaro with access to all data generated from
the Research Studies and, upon completion of the Research Studies, a summary of
the results of the Research Studies with respect to the Research Materials. Upon
completion of the Research Studies, Investigator shall return to Lakaro all
Research Materials in Investigator's possession.

     6.  Investigator will not use the data or results that is produced from
work with the Research Materials for any purpose other than determining
Investigator's interest, if any, in entering into a business relationship with
Lakaro with respect to the Research Materials.

     7.  Investigator may not publish or otherwise disclose data or results
obtained using the Research Materials provided without Lakaro's prior written
approval.

     8.  Unless otherwise expressly provided in writing by Lakaro, no right or
license in or to patents, patent applications, trade secrets or other
intellectual property rights of Lakaro, is granted or implied hereunder, except
for the sole purpose of conducting the studies specifically described herein.
Should a patentable invention or inventions result or arise from the
Investigator's conduct of the Research Studies where proprietary materials of
Investigator are utilized, Investigator and Lakaro shall pursue applications for
jointly-held patents in connection with such invention or inventions.

     9.  Investigator acknowledges that the Research Materials are the
confidential property of Lakaro and that in the course of performing the
research studies, Investigator may receive confidential technical and business
information of Lakaro ("Information").  Investigator hereby agrees not to use
the Information except for the purpose of conducting the Research Studies, and
not to disclose the Information to third parties without the express written
permission of Lakaro, except that Investigator shall not be prevented from using
or disclosing Information:

     (a) that is approved in writing by Lakaro for release by Investigator
without restrictions; or

     (b) that Investigator can demonstrate by written records was previously
known to Investigator; or
<PAGE>

     (c) which is now public knowledge, or becomes public knowledge, or becomes
         public knowledge in the future, other than through acts of omissions of
         Investigator in violation of this Section 9;

     (d) which is lawfully obtained by Investigator from sources independent of
         Lakaro who have a lawful right to disclose such Information; or

     (e) which is independently developed or acquired by personnel of
         Investigator who have not had access to, or knowledge of, the
         Information supplied by Lakaro.

In case Information is provided in oral form, the above obligation shall apply
only to the extent such oral Information has been confirmed in writing to the
Investigator and marked Confidential within forty five (45) days after the date
of oral disclosure. The obligations of Investigator under the terms of this
Section 9 shall remain in effect for five (5) years after the effective date of
this Agreement. The Investigator shall be entitled to retain for its legal files
a copy of all Information received under this Agreement for the sole purpose of
determining the scope and effect of its confidentiality obligations hereunder.

     10. Investigator shall pay Lakaro the amount of *** for one (1) gram in
the Research Materials, which amount shall include all applicable taxes and
shipping charges.

     11. Upon the satisfactory conclusion of the Research Studies, Investigator
shall have a two month exclusive period in which to enter into a license and co-
development agreement with Lakaro for the subject indications.

     12. Lakaro shall have the right to publicize the existence of the
relationship reflected in this Agreement following the prior written approval by
Investigator of the proposed publication in each case.

     13. Investigator shall indemnify and hold harmless Lakaro, its employees
or agents from and against all loss or expense by reason of any liability
imposed by law upon Lakaro, provided that such loss or expense is due, or
claimed to be due, as a result of negligence or willful acts or omissions by
Investigator.

     14. LAKARO PROVIDES NO WARRANTIES FOR THE RESEARCH MATERIALS, EXPRESS
OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTORY OR OTHERWISE, AND
SIGNALSITE SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

     15. This Agreement shall be governed by, and construed and interpreted in
accordance with, the laws of the State of Israel, without reference to conflict
of laws principles. Both parties will use their best efforts to settle all
disputes amicably. All disputes and differences of any kind related to this
Agreement which cannot be solved amicably by the parties shall be referred to
arbitration under the Rules of Arbitration of the International Chamber of
Commerce by one arbitrator appointed in accordance with those Rules. The
arbitration shall take place in London and shall be conducted in the English
language. The award of the arbitrator shall be final and binding on both
parties. The parties bind themselves to carry out the awards of the arbitrator.

     16. No modification to this Agreement, nor any waiver of any rights,
shall be effective unless assented to in writing by the party to be charged and
the waiver of any breach or default shall not constitute a waiver of any other
right hereunder or any subsequent breach or default.  This Agreement constitutes
the entire and exclusive Agreement between the parties hereto with respect to
the subject matter hereof and supersedes and cancels all previous registrations,
agreements, commitments and writings in respect thereof.

     17. Either party may assign this Agreement to a parent, subsidiary,
affiliate or division of that party following written notification of such
assignment to the other party.

     18. Each person signing below and each Party on whose behalf such person
executes this Agreement warrants that he or it, as the case may be, has the
authority to enter this Agreement and perform or cause the party on whose behalf
he has signed to perform the obligations hereunder.
<PAGE>

     19. Description and amount of the Research Materials to be provided by
Lakaro   ***

     20. Description of the Research Studies to be conducted:
         ***

Lakaro                        Investigator

By: /s/ Benjamin Corn              By: /s/ James Russell, Ph.D.
   ----------------------             ---------------------------

Print Name: Benjamin Corn          Print Name: James Russell, Ph.D.

Title: President                   Title: Executive Vice President,
                                            Chief Science Officer

Date: December 27, 1999            Date: December 17, 1999<PAGE>

                                                                   EXHIBIT 10.14

                      [LOGO OF KERYX BIOPHARMACEUTICALS]

                                                                Bob Trachtenberg
                                                                 General Counsel

May 15, 2000

Pierre Honore
Novo Nordisk

Re: Transfer of SignalSite R&D Agreement

Dear Pierre,

I write to request the approval of Novo Nordisk to the assumption by Keryx
Biopharmaceuticals of the agreement executed by Novo Nordisk and SignalSite,
Inc. on June 15, 1999.

Please see the attached letter from Children's Medical Center Corporation, the
licensor, certifying that Keryx has the exclusive rights to the KinAce
technology. In addition, on behalf of Keryx, I certify that Keryx shall be bound
by the terms and conditions of the SignalSite agreement.

Please indicate Novo Nordisk's consent by signing this letter below and
returning it to me at 212-207-9760. We would appreciate receiving a hard copy of
the signed letter in the mail to our offices in Jerusalem.

Thank you for your prompt attention to this matter.

Best regards,

/s/ Bob Trachtenberg

Bob Trachtenberg

Agreed:

/s/ Pierre Honore
---------------------------

Name:  PIERRE HONORE
Title: DIRECTOR, SCIENTIFIC LICENSING
Date:  MAY 18, 2000

              216 Jaffa Road, Sha'arei Ha'ir . Jerusalem . 94383

<PAGE>

            RESEARCH MATERIAL TRANSFER AND COLLABORATION  AGREEMENT
            -------------------------------------------------------

SignalSite, Inc., a corporation organized under the laws of the State of
Delaware, USA, with offices at 787 Seventh Avenue, NY, NY  10019 and 216 Jaffa
Road, Jerusalem 94383 Israel ("SignalSite"), will provide research material to
Novo Nordisk, at 2880 Bagsvared, Copenhagen, Denmark ("Investigator") on the
terms and conditions set forth in this Research Material Transfer Agreement
("Agreement").

     1.   SignalSite will generate novel peptides based upon a list of kinases
supplied by Investigator to be used as research material as further described in
Section 19 ("Research Materials") and section 20("Research Studies"). The
Investigator shall also supply SignalSite with an indication of the amount of
specific peptides it anticipates requiring for testing to be performed pursuant
to this Agreement. It is anticipated that the area of focus will be diabetes,
but the scope of the collaboration need not be limited to diabetes.

     2.   Investigator agrees that any and all Research Materials will be used
under suitable containment conditions solely for in vitro and in vivo laboratory
studies or animal testing, and will not be used in humans.  Investigator
acknowledges that the Research Materials are not intended for human use and,
pursuant to United States Food and Drug Administration regulations, animals
receiving Research Materials and by-products of such animals may not enter the
food chain.  Investigator will comply with all federal, state and local laws and
regulations applicable to the Research Materials.

     3.   The Research Materials are being provided to Investigator pursuant to
a limited license, the sole purpose of which shall be for Investigator to test
the peptides to determine their efficacy in the treatment of diabetes or other
diseases identified by the parties. Investigator agrees that the Research
Materials will be used solely to conduct research studies to determine the
feasibility of SignalSite's concept as it relates to diabetes and, should the
parties so agree, other diseases, as set forth in more detail in Section 20
("Research Studies"), and will not be used for any commercial purposes.
Investigator further agrees that it shall not use the Research Materials to make
peptide derivatives or peptidomimetics and that Research Materials will not be
transferred or provided to third parties either within or outside the
Investigator's premises without SignalSite's prior written approval.

     4.   SignalSite shall generate the Research Materials within four (4)
months after receiving the list of kinases from Investigator. Investigator shall
have up to four (4)  months from receipt of the Research Materials to test them
against its in vitro screen.

     5.   SignalSite will work with Investigator to develop the research test
plan. Investigator shall provide SignalSite with access to all data generated
from the research and testing, including a general outline of the assays used by
Investigator in the testing of the Research Materials. *** shall have the right
to approve the assays used in the testing of the Research Materials. Upon
completion of the Research Studies, Investigator shall return to *** all
Research Materials in Investigator's possession.

     6.   The parties will communicate at least bi-weekly during the conduct of
the Research Studies by conference call and written updates describing all
results and the accompanying data. Within thirty (30) days after completion of
the Research Studies, Investigator will provide to SignalSite a written summary
of data and results obtained using the Research Materials.

     7.   Investigator may not publish or otherwise disclose data or results
obtained using the Research Materials provided without SignalSite's prior
written approval.

     8.   SignalSite shall retain all right, title and interest relating to or
arising from the Research Materials, the Research Studies to be conducted and
existing uses thereof, including but not limited to all right, title and
interest in patents, patent applications, trade secrets and other intellectual
property rights arising from the Research Materials and/or the Research Studies.
Unless otherwise expressly provided in writing by SignalSite, no right or
license in or to patents, patent applications, trade secrets or other
intellectual property rights of SignalSite, is granted or implied hereunder,
except for the sole purpose of conducting the studies specifically described
herein.

     9.   Investigator acknowledges that the Research Materials are the
confidential property of SignalSite and that in the course of performing the
research studies, Investigator will receive confidential technical and business
information of SignalSite ("Information").  Investigator hereby agrees not to
use the Information except for the purpose of conducting the Research Studies,
and not to disclose the Information to third parties without the express written
permission of SignalSite, except that Investigator shall not be prevented from
using or disclosing Information:

     (a)  that is approved in writing by SignalSite for release by Investigator
          without restrictions; or
<PAGE>

     (b)  that Investigator can demonstrate by written records was previously
          known to Investigator; or

     (c)  which is now public knowledge, or becomes public knowledge, or becomes
          public knowledge in the future, other than through acts of omissions
          of Investigator in violation of this Section 9;

     (d)  which is lawfully obtained by Investigator from sources independent of
          SignalSite who have a lawful right to disclose such Information; or

     (e)  which is independently developed or acquired by personnel of
          Investigator who have not had access to, or knowledge of, the
          Information supplied by SignalSite.

In case Information is provided in oral form, the above obligation shall apply
only to the extent such oral Information has been confirmed in writing to the
Investigator and marked Confidential within forty five (45) days after the date
of oral disclosure. The obligations of Investigator under the terms of this
Section 9 shall remain in effect for five (5) years after the effective date of
this Agreement. The Investigator shall be entitled to retain for its legal files
a copy of all Information received under this Agreement for the sole purpose of
determining the scope and effect of its confidentiality obligations hereunder.

     10.  Investigator shall pay SignalSite the amount of *** as applicable as
compensation for expenses and overhead incurred in the generation of the
Research Materials.

     11.  Upon the satisfactory conclusion of the Research Studies, Investigator
shall have a two month exclusive period in which to enter into a license and co-
development agreement with SignalSite.

     12.  SignalSite shall have the right to publicize the existence of the
relationship reflected in this Agreement following the prior written approval by
Investigator of the proposed publication in each case.

     13.  Investigator shall indemnify and hold harmless SignalSite, its
employees or agents from and against all loss or expense by reason of any
liability imposed by law upon SignalSite, provided that such loss or expense is
due, or claimed to be due, as a result of negligence or willful acts or
omissions by Investigator.

     14.  SIGNALSITE PROVIDES NO WARRANTIES FOR THE RESEARCH MATERIALS, EXPRESS
OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTORY OR OTHERWISE, AND
SIGNALSITE SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

     15.  This Agreement shall be governed by, and construed and interpreted in
accordance with, the laws of the State of Israel,  without reference to conflict
of laws principles. Both parties will use their best efforts to settle all
disputes amicably. All disputes and differences of any kind related to this
Agreement which cannot be solved amicably by the parties shall be referred to
arbitration under the Rules of Arbitration of the International Chamber of
Commerce by one arbitrator appointed in accordance with those Rules. The
arbitration shall take place in London and shall be conducted in the English
language. The award of the arbitrator shall be final and binding on both
parties. The parties bind themselves to carry out the awards of the arbitrator.

     16.  No modification to this Agreement, nor any waiver of any rights, shall
be effective unless assented to in writing by the party to be charged and the
waiver of any breach or default shall not constitute a waiver of any other right
hereunder or any subsequent breach or default. This Agreement constitutes the
entire and exclusive Agreement between the parties hereto with respect to the
subject matter hereof and supersedes and cancels all previous registrations,
agreements, commitments and writings in respect thereof.

     17.  Either party may assign this Agreement to a parent, subsidiary,
affiliate or division of that party following written notification of such
assignment to the other party.

     18.  Each person signing below and each Party on whose behalf such person
executes this Agreement warrants that he or it, as the case may be, has the
authority to enter this Agreement and perform or cause the party on whose behalf
he has signed to perform the obligations hereunder.
<PAGE>

     19.  Description and amount of the Research Materials to be provided by
Signal Site :

     ***

     20.  Description of the Research Studies to be conducted:

A)   ***

B)   ***

C)   ***

SignalSite                              Investigator

                                                       ,
By:/s/ Benjamin Corn, M.D.             By:/s/ P. Honore
   -----------------------                --------------
                                                            ,
Print Name: Benjamin Corn, M.D.        Print Name: P. Honore
Title:  Chief Executive Officer        Title: Director, HC Business Development

Date:  June 17, 1999                   Date:  June 17, 1999

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]